ArticleCancer prevention research (Philadelphia, Pa.)2010
The origins and implications of intratumor heterogeneity.
Article in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.BMC cancer · 2015Pooled it
- A new cancer progression model: From synthetic tumors to real data and back.PLoS computational biology · 2026Article
- Review
- Hippo pathway controls biopterin metabolism to shield adjacent cells from ferroptosis in lung cancer.EMBO reports · 2025Article
- Proteomic profiling reveals common and region-specific protein signatures underlying tumor heterogeneity in cholangiocarcinoma.Scientific reports · 2025Article
- Cancer stem cells in meningiomas: novel insights and therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Review
- Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Network-based transfer of pan-cancer immunotherapy responses to guide breast cancer prognosis.NPJ systems biology and applications · 2025Article
- Deep Learning Predicts Subtype Heterogeneity and Outcomes in Luminal A Breast Cancer Using Routinely Stained Whole-Slide Images.Cancer research communications · 2025Article
- Progressive Dynamics of Cancer Stem Cells in Oral Squamous Cell Carcinoma.Current cancer drug targets · 2025Article
- The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.The Journal of biological chemistry · 2024Review
- Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics.European journal of medical research · 2024Article
- Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.JCI insight · 2024Article
- scGAL: unmask tumor clonal substructure by jointly analyzing independent single-cell copy number and scRNA-seq data.BMC genomics · 2024Article
- Heterogeneity of computational pathomic signature predicts drug resistance and intra-tumor heterogeneity of ovarian cancer.Translational oncology · 2024Article
- miR-617 interacts with the promoter ofFrontiers in oncology · 2024Article
- Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model.Scientific reports · 2023Article
- Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.Breast cancer research and treatment · 2023Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Human tumors often display startling intratumor heterogeneity in various features including histology, gene expression, genotype, and metastatic and proliferative potential. This phenotypic and genetic heterogeneity plays an important role in neoplasia, cancer progression, and therapeutic resistance. In this issue of the journal (beginning on page 1388), Merlo et al. report their use of molecular data from 239 patients with Barrett's esophagus to evaluate the propensity of major diversity indices for predicting progression to esophageal adenocarcinoma. This work helps elucidate the implications of molecular heterogeneity for the evolution of neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.